EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: Verastem, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
This description comes directly from the study's public registry record.
Verastem Call Center · 7812924204 · VS-7375-202TrialSupport@verastem.com
Ting Wu, MD · VS-7375-202Medical@verastem.com
Always discuss trial participation with your own doctor first.
| START LA | Los Angeles, California, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| START Fort Worth | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07659782